Context Therapeutics Inc. — Director's Dealing 2021

Oct 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Context Therapeutics Inc. (CNTX)
CIK: 0001842952
Period of Report: 2021-10-22

Reporting Person: Lehr Martin A. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-22	Common Stock	P	10000	$5	Acquired	99583	Direct
2021-10-22	Common Stock	O	52680	$7.14	Acquired	52680	Indirect
2021-10-22	Common Stock	C	210722	—	Acquired	263402	Indirect
2021-10-22	Common Stock	C	586476	—	Acquired	849878	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-22	Warrant (right to buy)	$7.14	O	52680	Acquired	2030-12-20	Common Stock (52680)	Indirect
2021-10-22	Series A Preferred Stock	$	C	210722	Disposed		Common Stock (210722)	Indirect
2021-10-22	Series Seed Preferred Stock	$	C	586476	Disposed		Common Stock (586476)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.

F2: Fully vested.

F3: Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.